Lineage Cell Therapeutics, Inc. Sale of Stock, Consideration Received on Transaction
Lineage Cell Therapeutics, Inc. (LCTX) reported Sale of Stock, Consideration Received on Transaction of $6.40 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2023-11-09
- Lineage Cell Therapeutics, Inc. sale of stock, consideration received on transaction for the quarter ending 2023-06-30 was $5.70M.
- Lineage Cell Therapeutics, Inc. sale of stock, consideration received on transaction for fiscal 2020 was $5.10M.
| Period end | Sale of Stock, Consideration Received on Transaction | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 9 month | Sale of Stock, Consideration Received on Transaction 12 month |
|---|---|---|---|---|
| 2023-09-30 | $6.40M 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $5.70M 10-Q · filed 2023-08-10 | |||
| 2020-12-31 | $5.10M 10-K · filed 2021-03-11 | |||
| 2017-02-28 | $18.80M 10-Q · filed 2017-05-10 | |||
| 2016-06-21 | $16.40M 10-Q · filed 2016-08-09 | |||
| 2016-06-16 | $16.40M 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |